title: Non-absorbable mesoporous silica for the development of protein sequestration therapies.
abstract: While our understanding of the molecular events leading to disease onset and progression have increased exponentially, our capacity to therapeutically intervene in these events with new chemical diversity has clearly fallen short of that pace. In the quest to readdress this situation, the drug discovery sector is slowly but increasingly exploring sources of alternative chemical matter, such as the ones provided by material science and nanotechnology. While new functional nano-sized materials hold great promise for the future, our lack of understanding of the long term safety implications associated with systemic exposure as well as the unclear regulatory path ahead hamper their present impact in drug development. Paradoxically, the exploitation of novel, functionally active micron-sized, synthetic, non-absorbable chemical matter, for the treatment or prevention of a number of epidemiologically significant conditions remains clearly underexplored. A combination of pre-existing evidence and future potential indicates that micron-sized mesoporous silica materials could be an untapped source of new drug candidates. These are free from both the dreaded high attrition associated with small molecule drug discovery and the uncertainties of nano-size technologies. This, together with the coming of age of synthetic methodologies to control particle size and shape; pore size and geometry; surface chemistry, bioconjugation and formulation, open up exciting possibilities to exploit this novel chemistry-biology therapeutic interface.
authors.affiliation: ARC Centre for Nanoscale BioPhotonics, Department of Chemistry and Bimolecular Sciences, Macquarie University, Sydney, 2109, Australia. Electronic address: alf.garcia@mq.edu.au.
authors.forename: Alfonso E
authors.initials: AE
authors.lastname: Garcia-Bennett
authors.affiliation: Diseases of the Developing World, RD Alternative Discovery & Development, GlaxoSmithKline, Severo Ochoa 2, Tres Cantos, 28760, Madrid, Spain. Electronic address: lluis.p.ballell@gsk.com.
authors.forename: Lluis
authors.initials: L
authors.lastname: Ballell
mesh_terms: D065966:Absorption, Physicochemical; D000327:Adsorption; D001781:Blood Component Removal / Q000379:methods*; D001798:Blood Proteins / Q000302:isolation & purification*; D002614:Chelating Agents / Q000737:chemistry; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure*; D058608:Nanopores / Q000648:ultrastructure*; D016062:Porosity; D012822:Silicon Dioxide / Q000737:chemistry*
chemical_list: D001798:Blood Proteins; D002614:Chelating Agents; D012822:Silicon Dioxide
keywords: Gastrointestinal adsorption; Mesoporous; Obesity; Oral administration; Protein sequestration; Silica